Satsuma Pharmaceuticals Logo
US80405P1075
A2PQPD
STSA

Satsuma Pharmaceuticals

Caricamento quotazioni...

Previsioni

Acquista
  4
Mantieni
  9
Vendi
  0

  • Satsuma Technologie announces auditor change after strategic review

    Satsuma Technologie said that Kreston Reeves LLP has resigned its appointment following discussions as part of a comprehensive strategic review and the appointment of a new leadership team in summer 2025. The board has launched a formal selection process for a new auditor to support the company’s growth plans. A statement from Kreston Reeves on its resignation will be circulated and published in accordance with the Companies Act 2006, and a new appointment will be announced in due course. » Altro su de.investing.com


  • Satsuma Technologie raises £163.6 million through successful convertible bond issuance

    Satsuma Technologie has raised £163.6 million by placing a second secured convertible bond, significantly surpassing its minimum target. The financing attracted prominent investors and allowed some to invest in Bitcoin instead of cash. The funds will be used for business expansion and to strengthen the company's Bitcoin-based treasury strategy. » Altro su de.investing.com


  • Tao Alpha becomes Satsuma Technology and adopts new ticker SATS.L

    Tao Alpha PLC is changing its name to Satsuma Technology PLC and adopting the new ticker symbol SATS.L on the London Stock Exchange. The rebranding is intended to highlight the company's focus on decentralized AI services and a Bitcoin-based treasury strategy, while existing shareholder rights remain unaffected. CEO Matthew Lodge emphasizes that this marks a step into a new phase of operational maturity. » Altro su de.investing.com

Nel 2014, Satsuma Pharmaceuticals ha già distribuito +0,29 di dividendi. L'ultimo pagamento è avvenuto a aprile 2014.

Dati finanziari dell'azienda

Nell'ultimo anno, Satsuma Pharmaceuticals ha registrato ricavi pari a 0,00 e un utile netto di 64,48M
(EUR) 2022
YoY
Ricavi 0,00 -
Utile lordo 0,00 -
Utile netto 64,48M 43,02%
EBITDA 54,36M 22,13%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
+31,30M
Numero di azioni
33,15M
Massimo/minimo a 52 settimane
+6,94 - +0,51
Dividendi No
Beta
0,1
Rapporto P/E
0,51
Rapporto PEG
+0,05
Rapporto P/B
0,17
Rapporto P/S
0,00

Profilo aziendale

Satsuma Pharmaceuticals, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige therapeutische Produkte für die akute Behandlung von Migräne entwickelt. Der führende Produktkandidat des Unternehmens ist STS101, eine Arzneimittel-Geräte-Kombination aus einer patentrechtlich geschützten Trockenpulverformulierung von Dihydroergotaminmesylat, die sich in SUMMIT-Phase-3-Wirksamkeitsstudien befindet und mit einem patentrechtlich geschützten, vorgefüllten Einweg- und Nasenspritzgerät selbst verabreicht werden kann. Satsuma Pharmaceuticals, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Nome
Satsuma Pharmaceuticals
CEO
John A. Kollins MBA
Sede centrale South San Francisco, ca
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
13/09/2019
Dipendenti 25

Simboli di borsa

Borsa Simbolo
NASDAQ
STSA
🍪

Parqet  usa i cookie. Scopri di più